DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Bellus Health, Inc. and Encourages Investors to Contact the Firm

NEW YORK–(BUSINESS WIRE) – Bragar Eagel & Squire, PC, a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of investors who bought Bellus Health. Inc. (NASDAQ: BLU) securities between September 5, 2019 and July 5, 2020 inclusive (the “Class Period”). Investors have until May 17, 2021 to apply to the court for appointment as the lead plaintiff in the lawsuit.

Click here to take part in the promotion.

Bellus is a clinical-stage biopharmaceutical company whose lead product is BLU-5937, which is developed for the treatment of chronic cough (which lasts for eight weeks) and other afferent hypersensitivity disorders.

Before the markets opened on July 6, 2020, the defendants revealed the truth about the effectiveness of BLU5937. They announced that the drug had failed a Phase 2 study in chronic cough patients who were unsuccessful with other treatments. In particular, BLU-5937 was not significantly better than placebo in reducing the frequency with which patients coughed. The phase 2 study only showed a “clinically important and statistically highly significant” effect in a subgroup of patients with high coughing numbers (around 32 per day). As a result, the company planned a Phase 2b study that focused on these patients.

In this news, which indicates that Bellus had fallen even further behind Merck in developing an FDA-approved treatment for refractory chronic cough, the company’s share price fell over 75% to close at 2.97 on July 8, 2020 USD.

The complaint, filed on March 16, 2021, alleges that the defendant’s system: (i) the investing public in relation to the business, business, drugs, drug development, competition, and the present and future business prospects of Have deceived Bellus; (ii) facilitated the Company’s public offer in September 2019 (“Offer”); (iii) created artificial demand for the Bellus common shares sold in the offering; (iv) enabled the Company to receive approximately $ 70 million in net proceeds from the sale of Bellus common stock under the Offering; and (v) caused Plaintiff and Class to purchase publicly traded Bellus common stock at artificially inflated prices

If you have purchased Bellus securities during the class period and have suffered a loss, have information, want to learn more about these claims, or have any questions about this announcement or your rights or interests in relation to these matters, please contact Brandon Walker, Melissa Fortunato or Marion Passmore by emailing [email protected], by phone at (212) 355-4648, or by completing this contact form. There are no costs or obligations for you.

About Bragar Eagel & Squire, PC:

Bragar Eagel & Squire, PC is a nationally recognized law firm with offices in New York, California and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivatives and other complex litigation in state and federal courts across the country. More information about the company can be found at www.bespc.com. Lawyer advertising. Previous results do not guarantee similar results.

Comments are closed.